Your browser doesn't support javascript.
loading
The development and benefits of metformin in various diseases / 医学前沿
Frontiers of Medicine ; (4): 388-431, 2023.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-982588
Biblioteca responsável: WPRO
ABSTRACT
Metformin has been used for the treatment of type II diabetes mellitus for decades due to its safety, low cost, and outstanding hypoglycemic effect clinically. The mechanisms underlying these benefits are complex and still not fully understood. Inhibition of mitochondrial respiratory-chain complex I is the most described downstream mechanism of metformin, leading to reduced ATP production and activation of AMP-activated protein kinase (AMPK). Meanwhile, many novel targets of metformin have been gradually discovered. In recent years, multiple pre-clinical and clinical studies are committed to extend the indications of metformin in addition to diabetes. Herein, we summarized the benefits of metformin in four types of diseases, including metabolic associated diseases, cancer, aging and age-related diseases, neurological disorders. We comprehensively discussed the pharmacokinetic properties and the mechanisms of action, treatment strategies, the clinical application, the potential risk of metformin in various diseases. This review provides a brief summary of the benefits and concerns of metformin, aiming to interest scientists to consider and explore the common and specific mechanisms and guiding for the further research. Although there have been countless studies of metformin, longitudinal research in each field is still much warranted.
Assuntos

Texto completo: Disponível Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Envelhecimento / Diabetes Mellitus Tipo 2 / Proteínas Quinases Ativadas por AMP / Hipoglicemiantes / Metformina Limite: Humanos Idioma: Inglês Revista: Frontiers of Medicine Ano de publicação: 2023 Tipo de documento: Artigo
Texto completo: Disponível Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Envelhecimento / Diabetes Mellitus Tipo 2 / Proteínas Quinases Ativadas por AMP / Hipoglicemiantes / Metformina Limite: Humanos Idioma: Inglês Revista: Frontiers of Medicine Ano de publicação: 2023 Tipo de documento: Artigo
...